<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00692913</url>
  </required_header>
  <id_info>
    <org_study_id>0217A-262</org_study_id>
    <secondary_id>2007_653</secondary_id>
    <nct_id>NCT00692913</nct_id>
  </id_info>
  <brief_title>A Study to Test the Effect of MK0217A on Vitamin D Inadequacy in Postmenopausal Women With Osteoporosis (0217A-262)</brief_title>
  <official_title>A Phase III (Phase V Program), Open-Label, Randomized, Referred-Care-Controlled, Clinical Trial to Evaluate the Efficacy and Safety of MK -0217A/Alendronate Sodium-70 mg/Vitamin D3 5600 I.U. Combination Tablet on Vitamin D Inadequacy in the Treatment of Osteoporosis in Postmenopausal Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <brief_summary>
    <textblock>
      A study designed to see if the study drug will increase blood levels of vitamin D, bone
      mineral density (BMD), improve biochemical markers of bone turnover, and reduce the number of
      falls as compared to women receiving standard care for osteoporosis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Serum Levels of 25-hydroxyvitamin D Below 20 ng/mL at Week 26</measure>
    <time_frame>Week 26</time_frame>
    <description>Percentage of participants with serum levels of 25-hydroxyvitamin D below
20 nanograms/milliliter (ng/mL) after 26 weeks of treatment with FOSAVANCE 5600 once weekly versus Referred-Care in postmenopausal women with osteoporosis and at increased risk of falls.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline at Week 26 in N-Telopeptides of Type 1 Collagen to Urine Creatinine Ratio</measure>
    <time_frame>Baseline and Week 26</time_frame>
    <description>N-Telopeptides of Type 1 Collagen to Urine Creatinine Ratio (NTx) is a urine biochemical marker of bone resorption and measured in nanomoles (nmol) Bone Collagen Equivalents (BCE)/millimoles (mmol) creatinine. The percent change was calculated as: [100 * ((Week 26/Baseline)-1)]. The greater the percent decrease from baseline, the greater the response to therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline at Week 26 in Bone-Specific Alkaline Phosphatase</measure>
    <time_frame>Baseline and Week 26</time_frame>
    <description>Bone-Specific Alkaline Phosphatase (BSAP) is a serum biochemical marker of bone formation and measured in micrograms/Liter (mcg/L). The percent change was calculated as: [100 * ((Week 26/Baseline)-1)]. The greater the percent decrease from baseline, the greater the response to therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Serum Levels of 25-hydroxyvitamin D Below 20 ng/mL at Week 52</measure>
    <time_frame>Week 52</time_frame>
    <description>Percentage of participants with serum levels of 25-hydroxyvitamin D below
20 ng/mL after 52 weeks of treatment (6 month extension study) with FOSAVANCE 5600 once weekly versus Referred-Care in postmenopausal women with osteoporosis and at increased risk of falls.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Lumbar Spine and Total Hip Bone Mineral Density</measure>
    <time_frame>Baseline and Week 52</time_frame>
    <description>Bone Mineral Density (BMD) as measured by Dual Energy X-Ray Absorptiometry (DEXA) and measured in g/cm^2 was obtained at baseline (visit 1) and Week 52 (visit 13) or at early study discontinuation visit. The percent change was calculated as: [100 * ((Week 52/Baseline)-1)]. The greater the percent change from baseline, the greater the response to therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Falls Per Participant</measure>
    <time_frame>Up to Week 52</time_frame>
    <description>Number of falls per participant was measured.
The fall event rate during the study period was defined as the number of adjudicated falls during the study period divided by the total patient-years in the study. Each participant was to be in the study for approximately one year.
In order to guide and standardize all procedures during the fall adjudication process, a Standard Operating Procedure for Fall Adjudication was created by the
SPONSOR and served as a guideline to standardize operational procedures for fall adjudication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline at Week 52 in N-Telopeptides of Type 1 Collagen to Urine Creatinine Ratio</measure>
    <time_frame>Baseline and Week 52</time_frame>
    <description>NTx is a urine biochemical marker of bone resorption and measured in nanomoles (nmol) Bone Collagen Equivalents (BCE)/millimoles (mmol) creatinine. The percent change was calculated as: [100 * ((Week 52/Baseline)-1)]. The greater the percent decrease from baseline, the greater the response to therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline at Week 52 in Bone-Specific Alkaline Phosphatase</measure>
    <time_frame>Baseline and Week 52</time_frame>
    <description>BSAP is a serum biochemical marker of bone formation and measured in micrograms/Liter (mcg/L). The percent change was calculated as: [100 * ((Week 52/Baseline)-1)]. The greater the percent decrease from baseline, the greater the response to therapy.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">515</enrollment>
  <condition>Osteoporosis</condition>
  <arm_group>
    <arm_group_label>FOSAVANCE 5600</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>alendronate sodium (+) cholecalciferol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Referred-Care Model</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Usual treatment for osteoporosis chosen and prescribed by patients' own physicians.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FOSAVANCE 5600 (Alendronate Sodium (+) cholecalciferol)</intervention_name>
    <description>FOSAVANCE 5600 international units (IU)(Alendronate Sodium 70 mg/Vitamin D 5600 IU) combination tablet once weekly for 6 months (Week 26) during the base period and an additional 6-month extension period (Week 52).</description>
    <arm_group_label>FOSAVANCE 5600</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Calcium Supplement 500 mg</intervention_name>
    <description>Calcium supplied locally by the investigator (containing 500 mg
calcium supplement) daily for 52 weeks (unless the patient's dietary intake of
calcium exceeds 1000 mg per day).</description>
    <arm_group_label>FOSAVANCE 5600</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Referred-Care Model</intervention_name>
    <description>Usual treatment for osteoporosis chosen and prescribed by patients' own physicians for 6 months (Week 26) during the base period and an additional 6-month extension period (Week 52).</description>
    <arm_group_label>Referred-Care Model</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female

          -  65 years or older

          -  Diagnosed with osteoporosis (Bone Mineral Density (BMD) T-score &lt;= -2.5 at spine or
             hip) or prior fragility fracture BMD T-score &lt;=-1.5 in at least one of the anatomic
             sites including lumbar spine, total hip, and femoral neck sites

          -  Postmenopausal

          -  Low levels of vitamin D as measured 25-hydroxyvitamin D

          -  Has fallen at least once within the past 12 months

        Exclusion Criteria:

          -  Unable to stand or sit upright for at least 30 minutes

          -  Has a bone disorder other than osteoporosis

          -  Contraindication to the use of FOSAVANCE
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Chile</country>
    <country>Colombia</country>
    <country>France</country>
    <country>Germany</country>
    <country>India</country>
    <country>Ireland</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Jordan</country>
    <country>Latvia</country>
    <country>Lebanon</country>
    <country>Lithuania</country>
    <country>Mexico</country>
    <country>Russian Federation</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>Turkey</country>
    <country>United Arab Emirates</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </removed_countries>
  <reference>
    <citation>Ralston SH, Binkley N, Boonen S, Kiel DP, Reginster JY, Roux C, Chen L, Rosenberg E, Santora A; FOCUS-D (FOSAVANCE vs. Standard Care-Use and Study of Vitamin D) Trial. Randomized trial of alendronate plus vitamin D3 versus standard care in osteoporotic postmenopausal women with vitamin D insufficiency. Calcif Tissue Int. 2011 Jun;88(6):485-94. doi: 10.1007/s00223-011-9482-4. Epub 2011 Apr 11.</citation>
    <PMID>21479913</PMID>
  </reference>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 4, 2008</study_first_submitted>
  <study_first_submitted_qc>June 4, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 6, 2008</study_first_posted>
  <results_first_submitted>July 20, 2011</results_first_submitted>
  <results_first_submitted_qc>July 20, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 15, 2011</results_first_posted>
  <last_update_submitted>February 14, 2017</last_update_submitted>
  <last_update_submitted_qc>February 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
    <mesh_term>Calcium, Dietary</mesh_term>
    <mesh_term>Alendronate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
http://engagezone.msd.com/ds_documentation.php</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>FOSAVANCE 5600</title>
          <description>Alendronate Sodium 70 mg/Vitamin D 5600 I.U. combination tablet once weekly plus a daily 500 mg elemental calcium supplement.</description>
        </group>
        <group group_id="P2">
          <title>Referred-Care</title>
          <description>Usual treatment for osteoporosis chosen and prescribed by patients' own physicians.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="257"/>
                <participants group_id="P2" count="258"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="228"/>
                <participants group_id="P2" count="228"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>FOSAVANCE 5600</title>
          <description>Alendronate Sodium 70 mg/Vitamin D 5600 I.U. combination tablet once weekly plus a daily 500 mg elemental calcium supplement.</description>
        </group>
        <group group_id="B2">
          <title>Referred-Care</title>
          <description>Usual treatment for osteoporosis chosen and prescribed by patients' own physicians.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="257"/>
            <count group_id="B2" value="258"/>
            <count group_id="B3" value="515"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72.9" spread="5.3"/>
                    <measurement group_id="B2" value="72.9" spread="5.9"/>
                    <measurement group_id="B3" value="72.9" spread="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="257"/>
                    <measurement group_id="B2" value="258"/>
                    <measurement group_id="B3" value="515"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Serum Levels of 25-hydroxyvitamin D Below 20 ng/mL at Week 26</title>
        <description>Percentage of participants with serum levels of 25-hydroxyvitamin D below
20 nanograms/milliliter (ng/mL) after 26 weeks of treatment with FOSAVANCE 5600 once weekly versus Referred-Care in postmenopausal women with osteoporosis and at increased risk of falls.</description>
        <time_frame>Week 26</time_frame>
        <population>Full Analysis Set Population (FAS) included participants who took at least one dose of study therapy during the entire treatment period of FOSAVANCE 5600 or who were
assigned to receive regular care and had data reported at least once post-randomization during the entire study period, and had efficacy measurements during the entire study period.</population>
        <group_list>
          <group group_id="O1">
            <title>FOSAVANCE 5600</title>
            <description>Alendronate Sodium 70 mg/Vitamin D 5600 I.U. combination tablet once weekly plus a daily 500 mg elemental calcium supplement.</description>
          </group>
          <group group_id="O2">
            <title>Referred-Care</title>
            <description>Usual treatment for osteoporosis chosen and prescribed by patients' own physicians.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Serum Levels of 25-hydroxyvitamin D Below 20 ng/mL at Week 26</title>
          <description>Percentage of participants with serum levels of 25-hydroxyvitamin D below
20 nanograms/milliliter (ng/mL) after 26 weeks of treatment with FOSAVANCE 5600 once weekly versus Referred-Care in postmenopausal women with osteoporosis and at increased risk of falls.</description>
          <population>Full Analysis Set Population (FAS) included participants who took at least one dose of study therapy during the entire treatment period of FOSAVANCE 5600 or who were
assigned to receive regular care and had data reported at least once post-randomization during the entire study period, and had efficacy measurements during the entire study period.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="221"/>
                <count group_id="O2" value="216"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.6"/>
                    <measurement group_id="O2" value="31.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <method_desc>The logistic regression model was adjusted by baseline 25-hydroxyvitamin D (25(OH)D) level stratum, age, and region.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.20</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.12</ci_lower_limit>
            <ci_upper_limit>0.35</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline at Week 26 in N-Telopeptides of Type 1 Collagen to Urine Creatinine Ratio</title>
        <description>N-Telopeptides of Type 1 Collagen to Urine Creatinine Ratio (NTx) is a urine biochemical marker of bone resorption and measured in nanomoles (nmol) Bone Collagen Equivalents (BCE)/millimoles (mmol) creatinine. The percent change was calculated as: [100 * ((Week 26/Baseline)-1)]. The greater the percent decrease from baseline, the greater the response to therapy.</description>
        <time_frame>Baseline and Week 26</time_frame>
        <population>Per-Protocol Population: excluded participants due to important deviations from the protocol that may substantially affect the results of the primary efficacy analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>FOSAVANCE 5600</title>
            <description>Alendronate Sodium 70 mg/Vitamin D 5600 I.U. combination tablet once weekly plus a daily 500 mg elemental calcium supplement.</description>
          </group>
          <group group_id="O2">
            <title>Referred-Care</title>
            <description>Usual treatment for osteoporosis chosen and prescribed by patients' own physicians.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline at Week 26 in N-Telopeptides of Type 1 Collagen to Urine Creatinine Ratio</title>
          <description>N-Telopeptides of Type 1 Collagen to Urine Creatinine Ratio (NTx) is a urine biochemical marker of bone resorption and measured in nanomoles (nmol) Bone Collagen Equivalents (BCE)/millimoles (mmol) creatinine. The percent change was calculated as: [100 * ((Week 26/Baseline)-1)]. The greater the percent decrease from baseline, the greater the response to therapy.</description>
          <population>Per-Protocol Population: excluded participants due to important deviations from the protocol that may substantially affect the results of the primary efficacy analysis.</population>
          <units>Percent Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="216"/>
                <count group_id="O2" value="226"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-57.06" lower_limit="-60.19" upper_limit="-53.68"/>
                    <measurement group_id="O2" value="-47.36" lower_limit="-51.23" upper_limit="-43.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Longitudinal Data Analysis Model</method>
            <method_desc>The model was adjusted by baseline 25-hydroxyvitamin D level stratum, age, and region.</method_desc>
            <param_type>Difference in Least-squares means</param_type>
            <param_value>-9.70</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-14.49</ci_lower_limit>
            <ci_upper_limit>-4.93</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline at Week 26 in Bone-Specific Alkaline Phosphatase</title>
        <description>Bone-Specific Alkaline Phosphatase (BSAP) is a serum biochemical marker of bone formation and measured in micrograms/Liter (mcg/L). The percent change was calculated as: [100 * ((Week 26/Baseline)-1)]. The greater the percent decrease from baseline, the greater the response to therapy.</description>
        <time_frame>Baseline and Week 26</time_frame>
        <population>Per-Protocol Population: excluded participants due to important deviations from the protocol that may substantially affect the results of the primary efficacy analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>FOSAVANCE 5600</title>
            <description>Alendronate Sodium 70 mg/Vitamin D 5600 I.U. combination tablet once weekly plus a daily 500 mg elemental calcium supplement.</description>
          </group>
          <group group_id="O2">
            <title>Referred-Care</title>
            <description>Usual treatment for osteoporosis chosen and prescribed by patients' own physicians.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline at Week 26 in Bone-Specific Alkaline Phosphatase</title>
          <description>Bone-Specific Alkaline Phosphatase (BSAP) is a serum biochemical marker of bone formation and measured in micrograms/Liter (mcg/L). The percent change was calculated as: [100 * ((Week 26/Baseline)-1)]. The greater the percent decrease from baseline, the greater the response to therapy.</description>
          <population>Per-Protocol Population: excluded participants due to important deviations from the protocol that may substantially affect the results of the primary efficacy analysis.</population>
          <units>Percent Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="223"/>
                <count group_id="O2" value="237"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-46.67" lower_limit="-49.32" upper_limit="-43.88"/>
                    <measurement group_id="O2" value="-39.60" lower_limit="-42.60" upper_limit="-36.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Longitudinal Data Analysis Model</method>
            <method_desc>The model was adjusted by baseline 25-hydroxyvitamin D level stratum, age, and region.</method_desc>
            <param_type>Difference in Least-squares mean</param_type>
            <param_value>-7.07</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-10.95</ci_lower_limit>
            <ci_upper_limit>-3.20</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Serum Levels of 25-hydroxyvitamin D Below 20 ng/mL at Week 52</title>
        <description>Percentage of participants with serum levels of 25-hydroxyvitamin D below
20 ng/mL after 52 weeks of treatment (6 month extension study) with FOSAVANCE 5600 once weekly versus Referred-Care in postmenopausal women with osteoporosis and at increased risk of falls.</description>
        <time_frame>Week 52</time_frame>
        <population>The FAS population included participants who took at least one dose of study therapy during the entire treatment period of FOSAVANCE 5600 or who were assigned to receive regular care and had data reported at least once post-randomization during the entire study period, and had efficacy measurements during the entire study period.</population>
        <group_list>
          <group group_id="O1">
            <title>FOSAVANCE 5600</title>
            <description>Alendronate Sodium 70 mg/Vitamin D 5600 I.U. combination tablet once weekly plus a daily 500 mg elemental calcium supplement.</description>
          </group>
          <group group_id="O2">
            <title>Referred-Care</title>
            <description>Usual treatment for osteoporosis chosen and prescribed by patients' own physicians.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Serum Levels of 25-hydroxyvitamin D Below 20 ng/mL at Week 52</title>
          <description>Percentage of participants with serum levels of 25-hydroxyvitamin D below
20 ng/mL after 52 weeks of treatment (6 month extension study) with FOSAVANCE 5600 once weekly versus Referred-Care in postmenopausal women with osteoporosis and at increased risk of falls.</description>
          <population>The FAS population included participants who took at least one dose of study therapy during the entire treatment period of FOSAVANCE 5600 or who were assigned to receive regular care and had data reported at least once post-randomization during the entire study period, and had efficacy measurements during the entire study period.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="212"/>
                <count group_id="O2" value="203"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.3"/>
                    <measurement group_id="O2" value="36.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <method_desc>The logistic regression model was adjusted by baseline 25-hydroxyvitamin D level stratum, age, and region.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.21</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.13</ci_lower_limit>
            <ci_upper_limit>0.35</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Lumbar Spine and Total Hip Bone Mineral Density</title>
        <description>Bone Mineral Density (BMD) as measured by Dual Energy X-Ray Absorptiometry (DEXA) and measured in g/cm^2 was obtained at baseline (visit 1) and Week 52 (visit 13) or at early study discontinuation visit. The percent change was calculated as: [100 * ((Week 52/Baseline)-1)]. The greater the percent change from baseline, the greater the response to therapy.</description>
        <time_frame>Baseline and Week 52</time_frame>
        <population>The FAS population included participants who took at least one dose of study therapy during the entire treatment period of FOSAVANCE 5600 or who were assigned to receive regular care and had data reported at least once post-randomization during the entire study period, and had efficacy measurements during the entire study period.</population>
        <group_list>
          <group group_id="O1">
            <title>FOSAVANCE 5600</title>
            <description>Alendronate Sodium 70 mg/Vitamin D 5600 I.U. combination tablet once weekly plus a daily 500 mg elemental calcium supplement.</description>
          </group>
          <group group_id="O2">
            <title>Referred-Care</title>
            <description>Usual treatment for osteoporosis chosen and prescribed by patients' own physicians.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Lumbar Spine and Total Hip Bone Mineral Density</title>
          <description>Bone Mineral Density (BMD) as measured by Dual Energy X-Ray Absorptiometry (DEXA) and measured in g/cm^2 was obtained at baseline (visit 1) and Week 52 (visit 13) or at early study discontinuation visit. The percent change was calculated as: [100 * ((Week 52/Baseline)-1)]. The greater the percent change from baseline, the greater the response to therapy.</description>
          <population>The FAS population included participants who took at least one dose of study therapy during the entire treatment period of FOSAVANCE 5600 or who were assigned to receive regular care and had data reported at least once post-randomization during the entire study period, and had efficacy measurements during the entire study period.</population>
          <units>Percent Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="227"/>
                <count group_id="O2" value="219"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Lumbar Spine (n= 226/ n=219)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.92" lower_limit="4.17" upper_limit="5.66"/>
                    <measurement group_id="O2" value="3.91" lower_limit="3.16" upper_limit="4.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Hip (n=227/ n=218)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.22" lower_limit="1.65" upper_limit="2.79"/>
                    <measurement group_id="O2" value="1.40" lower_limit="0.83" upper_limit="1.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.047</p_value>
            <method>Traditional Longitudinal data analysis</method>
            <method_desc>The model was adjusted by baseline 25-hydroxyvitamin D level stratum, age, and region.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>1.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.01</ci_lower_limit>
            <ci_upper_limit>2.00</ci_upper_limit>
            <estimate_desc>FOSAVANCE minus Referred-Care. Analysis was for Lumbar Spine.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.035</p_value>
            <method>Traditional Longitudinal data analysis</method>
            <method_desc>The model was adjusted by baseline 25-hydroxyvitamin D level stratum, age, and region.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>0.82</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.06</ci_lower_limit>
            <ci_upper_limit>1.58</ci_upper_limit>
            <estimate_desc>FOSAVANCE minus Referred-Care. Analysis was for Total Hip.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Falls Per Participant</title>
        <description>Number of falls per participant was measured.
The fall event rate during the study period was defined as the number of adjudicated falls during the study period divided by the total patient-years in the study. Each participant was to be in the study for approximately one year.
In order to guide and standardize all procedures during the fall adjudication process, a Standard Operating Procedure for Fall Adjudication was created by the
SPONSOR and served as a guideline to standardize operational procedures for fall adjudication.</description>
        <time_frame>Up to Week 52</time_frame>
        <population>Intent-to-Treat (ITT) population included all randomized participants within the treatment group to which they were randomized regardless of whether or not a participant may have dropped out in the base or continued into the extension study.</population>
        <group_list>
          <group group_id="O1">
            <title>FOSAVANCE 5600</title>
            <description>Alendronate Sodium 70 mg/Vitamin D 5600 I.U. combination tablet once weekly plus a daily 500 mg elemental calcium supplement.</description>
          </group>
          <group group_id="O2">
            <title>Referred-Care</title>
            <description>Usual treatment for osteoporosis chosen and prescribed by patients' own physicians.</description>
          </group>
        </group_list>
        <measure>
          <title>Falls Per Participant</title>
          <description>Number of falls per participant was measured.
The fall event rate during the study period was defined as the number of adjudicated falls during the study period divided by the total patient-years in the study. Each participant was to be in the study for approximately one year.
In order to guide and standardize all procedures during the fall adjudication process, a Standard Operating Procedure for Fall Adjudication was created by the
SPONSOR and served as a guideline to standardize operational procedures for fall adjudication.</description>
          <population>Intent-to-Treat (ITT) population included all randomized participants within the treatment group to which they were randomized regardless of whether or not a participant may have dropped out in the base or continued into the extension study.</population>
          <units>Number of Falls</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="257"/>
                <count group_id="O2" value="258"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.51" spread="1.53"/>
                    <measurement group_id="O2" value="0.45" spread="0.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.675</p_value>
            <method>Zero-Inflated Poisson Regression</method>
            <method_desc>Adjusted by the terms for treatment, baseline 25(OH) D level stratum, age, and region and offset variable of log (total patient-years in the study).</method_desc>
            <param_type>Difference of falls (falls/patient-year)</param_type>
            <param_value>0.03</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.08</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.12</ci_lower_limit>
            <ci_upper_limit>0.19</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline at Week 52 in N-Telopeptides of Type 1 Collagen to Urine Creatinine Ratio</title>
        <description>NTx is a urine biochemical marker of bone resorption and measured in nanomoles (nmol) Bone Collagen Equivalents (BCE)/millimoles (mmol) creatinine. The percent change was calculated as: [100 * ((Week 52/Baseline)-1)]. The greater the percent decrease from baseline, the greater the response to therapy.</description>
        <time_frame>Baseline and Week 52</time_frame>
        <population>Per-Protocol Population: excluded patients due to important deviations from the protocol that may substantially affect the results of the primary efficacy analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>FOSAVANCE 5600</title>
            <description>Alendronate Sodium 70 mg/Vitamin D 5600 I.U. combination tablet once weekly plus a daily 500 mg elemental calcium supplement.</description>
          </group>
          <group group_id="O2">
            <title>Referred-Care</title>
            <description>Usual treatment for osteoporosis chosen and prescribed by patients' own physicians.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline at Week 52 in N-Telopeptides of Type 1 Collagen to Urine Creatinine Ratio</title>
          <description>NTx is a urine biochemical marker of bone resorption and measured in nanomoles (nmol) Bone Collagen Equivalents (BCE)/millimoles (mmol) creatinine. The percent change was calculated as: [100 * ((Week 52/Baseline)-1)]. The greater the percent decrease from baseline, the greater the response to therapy.</description>
          <population>Per-Protocol Population: excluded patients due to important deviations from the protocol that may substantially affect the results of the primary efficacy analysis.</population>
          <units>Percent Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="216"/>
                <count group_id="O2" value="227"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-58.42" lower_limit="-61.58" upper_limit="-54.99"/>
                    <measurement group_id="O2" value="-50.07" lower_limit="-54.01" upper_limit="-45.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>Longitudinal Data Analysis Model</method>
            <method_desc>The model was adjusted by baseline 25-hydroxyvitamin D level stratum, age, and region.</method_desc>
            <param_type>Difference in Least Squares Means</param_type>
            <param_value>-8.35</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-13.19</ci_lower_limit>
            <ci_upper_limit>-3.54</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline at Week 52 in Bone-Specific Alkaline Phosphatase</title>
        <description>BSAP is a serum biochemical marker of bone formation and measured in micrograms/Liter (mcg/L). The percent change was calculated as: [100 * ((Week 52/Baseline)-1)]. The greater the percent decrease from baseline, the greater the response to therapy.</description>
        <time_frame>Baseline and Week 52</time_frame>
        <population>Per-Protocol Population: excluded patients due to important deviations from the protocol that may substantially affect the results of the primary efficacy analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>FOSAVANCE 5600</title>
            <description>Alendronate Sodium 70 mg/Vitamin D 5600 I.U. combination tablet once weekly plus a daily 500 mg elemental calcium supplement.</description>
          </group>
          <group group_id="O2">
            <title>Referred-Care</title>
            <description>Usual treatment for osteoporosis chosen and prescribed by patients' own physicians.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline at Week 52 in Bone-Specific Alkaline Phosphatase</title>
          <description>BSAP is a serum biochemical marker of bone formation and measured in micrograms/Liter (mcg/L). The percent change was calculated as: [100 * ((Week 52/Baseline)-1)]. The greater the percent decrease from baseline, the greater the response to therapy.</description>
          <population>Per-Protocol Population: excluded patients due to important deviations from the protocol that may substantially affect the results of the primary efficacy analysis.</population>
          <units>Percent Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="223"/>
                <count group_id="O2" value="237"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-51.21" lower_limit="-53.79" upper_limit="-48.48"/>
                    <measurement group_id="O2" value="-43.13" lower_limit="-46.18" upper_limit="-39.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Longitudinal Data Analysis Model</method>
            <method_desc>The model was adjusted by baseline 25-hydroxyvitamin D level stratum, age, and region.</method_desc>
            <param_type>Difference in Least Squares Mean</param_type>
            <param_value>-8.07</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-11.94</ci_lower_limit>
            <ci_upper_limit>-4.21</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>FOSAVANCE 5600 group: participants who took at least 1 dose were included (254 out of 257 patients). All patients randomized in the referred-care group were included regardless of whether they took 1 dose of therapy as prescribed by their physicians.</desc>
      <group_list>
        <group group_id="E1">
          <title>FOSAVANCE 5600</title>
          <description>Alendronate Sodium 70 mg/Vitamin D 5600 I.U. combination tablet once weekly plus a daily 500 mg elemental calcium supplement.</description>
        </group>
        <group group_id="E2">
          <title>Referred-Care</title>
          <description>Usual treatment for osteoporosis chosen and prescribed by patients' own physicians.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (13.0)</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="258"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina Unstable</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="254"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>Cardiac Failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>Coronary Artery Disease</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="254"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>Electromechanical Dissociation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>Myocardial Infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>Sick Sinus Syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="258"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye Haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="258"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain Upper</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>Faecaloma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>Gastric Ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>Gastroesophageal Reflux Disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>Intestinal Obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>Retroperitoneal Haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="258"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>Local Swelling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>Non-Cardiac Chest Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="258"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="258"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bacterial Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>Enterovirus Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>Gastroenteritis Viral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>Malaria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>Peritonsillar Abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>Subacute Endocarditis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="258"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ankle Fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>Hip Fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>Meniscus Lesion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>Pubis Fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="258"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="258"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>Intervertebral Disc Protrusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>Lumbar Spinal Stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>Spinal Column Stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="258"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Basal Cell Carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>Colon Cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>Oesophageal Squamous Cell Carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>Ovarian Epithelial Cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>Pancreatic Carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>Uterine Cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="258"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Carotid Artery Stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>Cerebral Ischaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>Cerebrovascular Accident</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>Facial Palsy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>Radiculopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>Transient Ischaemic Attack</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>Unresponsive to Stimuli</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>Vascular Dementia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="258"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>Renal Artery Stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>Renal Failure Acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="258"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Respiratory Failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>Pulmonary Congestion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>Respiratory Failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="258"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Orthostatic Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>Peripheral Arterial Occlusive disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis Superficial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="258"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (13.0)</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="61" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="70" subjects_at_risk="258"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="254"/>
                <counts group_id="E2" events="14" subjects_affected="13" subjects_at_risk="258"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="254"/>
                <counts group_id="E2" events="18" subjects_affected="14" subjects_at_risk="258"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="21" subjects_affected="13" subjects_at_risk="254"/>
                <counts group_id="E2" events="19" subjects_affected="14" subjects_at_risk="258"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="24" subjects_affected="20" subjects_at_risk="254"/>
                <counts group_id="E2" events="23" subjects_affected="21" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" events="14" subjects_affected="12" subjects_at_risk="254"/>
                <counts group_id="E2" events="22" subjects_affected="21" subjects_at_risk="258"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="254"/>
                <counts group_id="E2" events="17" subjects_affected="13" subjects_at_risk="258"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The SPONSOR must have the opportunity to review all proposed abstracts, manuscripts,or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the SPONSOR as confidential must be deleted prior to submission. SPONSOR review can be expedited to meet publication guidelines.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp</organization>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

